WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522398
Description: QNZ46 is a NMDA receptor antagonist. QNZ46 inhibits NMDA receptor function in a noncompetitive and voltage-independent manner by an unconventional mechanism that requires binding of glutamate to the GluN2 subunit, but not glycine binding to the GluN1 subunit. QNZ46 could provide an opportunity for the development of pharmacological tools and therapeutic agents that target NMDA receptors at a new site and modulate function by a novel mechanism. NMDA receptors are ionotropic glutamate receptors that mediate excitatory synaptic transmission and have been implicated in several neurological diseases.
MedKoo Cat#: 522398
Chemical Formula: C24H17N3O6
Exact Mass: 443.11174
Molecular Weight: 443.42
Elemental Analysis: C, 65.01; H, 3.86; N, 9.48; O, 21.65
Synonym: QNZ46; QNZ-46; QNZ 46.
IUPAC/Chemical Name: (E)-4-(6-methoxy-2-(3-nitrostyryl)-4-oxoquinazolin-3(4H)-yl)benzoic acid
SMILES Code: O=C(O)C1=CC=C(N2C(/C=C/C3=CC=CC([N+]([O-])=O)=C3)=NC4=C(C=C(OC)C=C4)C2=O)C=C1
1: Hansen KB, Traynelis SF. Structural and mechanistic determinants of a novel
site for noncompetitive inhibition of GluN2D-containing NMDA receptors. J
Neurosci. 2011 Mar 9;31(10):3650-61. doi: 10.1523/JNEUROSCI.5565-10.2011. PubMed
PMID: 21389220; PubMed Central PMCID: PMC3063124.